Wednesday, October 21 - Sunday, October 25
Venatorx Pharmaceuticals has been awarded a Phase 1 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. The company may receive up to $600,000 of funding under...
|You are using a browser that is not supported. Please consider changing your browser|